Geistlich Pharma North America introduced vallos™, the company’s first demineralized allograft.
With two formulations for treatment flexibility, vallos granules are suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line offers:
Verified osteoinductive potential in every lot
Consistent product quality
Proven regenerative capacity by exhibiting all five elements of bone formation
Vital bone after 18-20 weeks
Demineralized vallos and vallos f offer clinicians more options to manage a variety of clinical indications, and are the first products to become part of the Geistlich Select family.
“We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, General Manager of Geistlich Pharma North America.
Geistlich Pharma North America introduced vallos™, the company's first demineralized allograft.
With two formulations for treatment flexibility, vallos granules are suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line offers:
Verified osteoinductive...
Geistlich Pharma North America introduced vallos™, the company’s first demineralized allograft.
With two formulations for treatment flexibility, vallos granules are suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line offers:
Verified osteoinductive potential in every lot
Consistent product quality
Proven regenerative capacity by exhibiting all five elements of bone formation
Vital bone after 18-20 weeks
Demineralized vallos and vallos f offer clinicians more options to manage a variety of clinical indications, and are the first products to become part of the Geistlich Select family.
“We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, General Manager of Geistlich Pharma North America.
Copy to clipboard 
